Ultra high throughput screening platform for drug discovery platform is capable of delivering several hundred thousand screening wells per day with a variety of assay technologies
The Automation Partnership, manufacturer of advanced automated systems, announced that it has reached agreement on the specifications of an ultra high throughput screening (uHTS) platform for the expanding drug discovery factory programme at GlaxoSmithKline's (GSK) Tres Cantos facility in Spain.
The technology, called Asset, is a fully integrated screening platform capable of delivering several hundred thousand screening wells per day with a variety of assay technologies and unattended operation.
Two Asset systems are currently in full operation and have been proven to routinely deliver uHTS throughputs with high quality data and reliability.
Richard Archer, CEO of The Automation Partnership, explains, "TAP has been a leader in adopting the principles of industrial automation and applying them to life sciences.
Asset is an example of this approach applied to uHTS and it is an important addition to our portfolio of advanced automation for drug discovery.
GSK is an industry leader in adapting industrial automation concepts to drug discovery and their confidence in TAP verifies our long held belief in this concept."
